Revolution Medicines, Inc. - Common Stock (RVMD)

Historical Holders from Q1 2020 to Q3 2025

Symbol
RVMD on Nasdaq
CUSIP
76155X100
Type / Class
Equity / Common Stock
Shares outstanding
186M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
192M
Holdings value
$8.95B
% of all portfolios
0.015%
Grand Portfolio weight change
+0%
Number of holders
311
Number of buys
173
Number of sells
-134
Average Value change %
+0%
Average buys %
+0.003%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revolution Medicines, Inc. - Common Stock (RVMD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 7.9% +15.7% $436M $63.5M 13.3M +17% Dapice Joshua J. Dec 31, 2024
JANUS HENDERSON GROUP PLC 6.1% +6.67% $530M $35.7M 11.4M +7.23% JANUS HENDERSON GROUP PLC Sep 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 5.5% $377M 10.3M Wellington Management Group LLP Jun 30, 2025
FMR LLC 5% $439M 9.4M FMR LLC Sep 30, 2025
BAKER BROS. ADVISORS LP 5% $359M 9.36M Baker Bros. Advisors LP Jun 30, 2025
BlackRock, Inc. 4.5% $334M 8.4M BlackRock, Inc. Jun 30, 2025

Institutional Holders of Revolution Medicines, Inc. - Common Stock (RVMD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 192M $8.95B +$87.1M $46.70 311
2025 Q2 191M $7.02B -$4.2M $36.79 304
2025 Q1 191M $6.78B -$112M $35.36 280
2024 Q4 193M $8.45B +$749M $43.74 278
2024 Q3 169M $7.66B +$1.88M $45.35 252
2024 Q2 168M $6.54B +$376M $38.81 222
2024 Q1 159M $5.12B +$13.5M $32.23 205
2023 Q4 297K $8.53M +$6.44M $29.02 4
2023 Q3 112M $3.1B +$8.76M $27.68 163
2023 Q2 112M $2.98B +$99.9M $26.75 136
2023 Q1 108M $2.34B +$421M $21.66 147
2022 Q4 88.2M $2.1B +$33.1M $23.82 131
2022 Q3 81M $1.6B +$213M $19.72 128
2022 Q2 71M $1.38B +$38.1M $19.49 122
2022 Q1 73.9M $1.89B +$15.7M $25.51 121
2021 Q4 73.3M $1.84B -$50.2M $25.17 111
2021 Q3 72.3M $1.99B +$49.8M $27.51 111
2021 Q2 70.3M $2.23B +$90.8M $31.74 125
2021 Q1 66.4M $3.05B +$427M $45.88 125
2020 Q4 57.3M $2.27B +$131M $39.59 114
2020 Q3 57M $1.98B +$340M $34.80 87
2020 Q2 46.9M $1.48B +$22.7M $31.57 72
2020 Q1 46.9M $1.03B +$1.02B $21.91 71